Antigen Express granted patent for AE37 immunotherapeutic vaccine: Generex Biotechnol

[News]

Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc., has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first "composition of matter" patent to be issued relating to one of their development products.

More... (http://www.news-medical.net/news/20100714/Antigen-Express-granted-patent-for-AE37-immunotherapeutic-vaccine-Generex-Biotechnology.aspx)